Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to -$1.65.

  • Prime Medicine's EPS (Weighted Average and Diluted) rose 27.27% to -$0.32 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.44, marking a year-over-year increase of 30.10%. This contributed to the annual value of -$1.65 for FY2024, which is 24.31% up from last year.
  • As of FY2024, Prime Medicine's EPS (Weighted Average and Diluted) stood at -$1.65, which was up 24.31% from -$2.18 recorded in FY2023.
  • In the past 5 years, Prime Medicine's EPS (Weighted Average and Diluted) registered a high of -$1.65 during FY2024, and its lowest value of -$14.19 during FY2021.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$2.67, with a median of -$2.18 in 2023.
  • As far as peak fluctuations go, Prime Medicine's EPS (Weighted Average and Diluted) crashed by 642.93% in 2021, and later spiked by 70.47% in 2022.
  • Over the past 5 years, Prime Medicine's EPS (Weighted Average and Diluted) (Yearly) stood at -$1.91 in 2020, then tumbled by 642.93% to -$14.19 in 2021, then spiked by 70.47% to -$4.19 in 2022, then surged by 47.97% to -$2.18 in 2023, then climbed by 24.31% to -$1.65 in 2024.